Synergistic effect of recombinant CD4-immunoglobulin in combination with azidothymidine, dideoxyinosine and 0.5 beta-monoclonal antibody on human immunodeficiency virus infection in vitro.
Data are presented which indicate that combinations of rCD4 immunoglobulin with azidothymidine, dideoxyinosine or 0.5 beta mouse monoclonal antibodies directed against the V3 region of HIV-1, were more effective in treatment of acute HIV infection in vitro than each compound alone. It is suggested that combination therapy with these compounds is more beneficial in treatment of HIV-infected patients than monotherapy, especially with respect to a reduction of the known side effects and the formation of resistant HIV strains after treatment with nucleoside analogues.
Ushijima
H
H
AIDS Research Center, National Institute of Health, Tokyo, Japan.
Kunisada
T
T
Kitamura
T
T
Müller
W E
WE
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016860:CD4 Immunoadhesins / Q000627:therapeutic use; D002478:Cells, Cultured; D016049:Didanosine / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D008214:Lymphocytes; D015215:Zidovudine / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D016860:CD4 Immunoadhesins; D015215:Zidovudine; D016049:Didanosine